Last reviewed · How we verify
heparin plus tirofiban
At a glance
| Generic name | heparin plus tirofiban |
|---|---|
| Also known as | brand name of tirofiban: Xinweining |
| Sponsor | Shenyang Northern Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Deferred Stent Trial in STEMI (NA)
- Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180) (PHASE3)
- Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention (PHASE2)
- Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention (PHASE3)
- European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial (PHASE3)
- Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (PHASE3)
- Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease (PHASE4)
- BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |